Danaher CORP /DE/

Danaher Corporation announced the appointment of Julie Sawyer Montgomery as its new President and Chief Executive Officer, effective October 1, 2026, succeeding Rainer Blair.

Danaher Corporation announced the issuance and sale of approximately CHF 1.90 billion in senior notes across seven series, maturing between 2031 and 2056, to fund general corporate purposes.

Danaher Corporation's annual shareholder meeting on May 5, 2026, saw overwhelming approval for the Amended and Restated Omnibus Incentive Plan and the election of directors.

Danaher Corporation enters into a new $5.0 billion 364-day revolving credit facility to provide liquidity support for its commercial paper program and general corporate needs.

Danaher Corporation announced a definitive agreement to acquire Masimo Corporation for $180 per share in cash, totaling approximately $9.9 billion.

Danaher Corporation announced the retirement of Dr. Jessica L. Mega from its Board of Directors, effective February 5, 2026, citing other professional commitments.

Danaher Corporation reported increased sales and net earnings for the third quarter of 2025, but significant impairment charges led to a decline in nine-month net earnings and diluted EPS.

Danaher Corporation reported a substantial decrease in net earnings and operating profit for the second quarter and first half of 2025, primarily driven by a significant intangible asset impairment charge in its Life Sciences segment, despite overall sales growth.

Danaher Corporation's first quarter 2025 sales decreased by 1.0% year-over-year, with core sales remaining flat, as the company navigates currency headwinds and tariff impacts.

Danaher Corporation's third-quarter results show a slight revenue increase but a decrease in earnings, impacted by market conditions and strategic investments.

Danaher Corporation's second-quarter results show a decrease in revenue and core sales, primarily driven by declines in the Biotechnology segment, while the Diagnostics segment showed growth.

Danaher Corporation's first quarter 2024 results show a decrease in core sales, particularly in the Biotechnology segment, impacting overall revenue and profitability.

Danaher Corporation reported a 3.0% increase in total sales to $24.57 billion in 2025, but net earnings from continuing operations declined to $3.6 billion, while announcing a pending $9.9 billion acquisition of Masimo Corporation.

Danaher's 2024 10-K filing reveals a year of flat revenue, strategic cost management, and a focus on long-term growth amidst global economic uncertainties and evolving market dynamics.

Danaher Corporation's 10-K filing provides a detailed description of its registered securities, including common stock and debt, along with executive compensation and corporate governance policies.

Linda Filler, a Director of Danaher Corp /De/, received 18 shares of common stock on July 31, 2026.

Elias A. Zerhouni, a Director of Danaher Corp /De/, received 237 shares of common stock on July 31, 2026.

Alan G Spoon, a Director of Danaher Corp /De/, received 230 shares of common stock on July 31, 2026.

Teri List, a Director of Danaher Corp /De/, received 16 shares of common stock on July 31, 2026.

A Shane Sanders, a Director of Danaher Corp /De/, received 211 shares of common stock on July 31, 2026.

Feroz Dewan, a Director of Danaher Corp /De/, received 171 shares of common stock on July 31, 2026.

Danaher Corporation announces its 2026 Annual Meeting of Shareholders, proposing director elections, auditor ratification, executive compensation advisory vote, and approval of an amended incentive plan.

Danaher Corporation has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Danaher Corporation's 2025 proxy statement details the election of directors, executive compensation, and corporate governance matters for the upcoming annual meeting.

Danaher Corporation has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Danaher Corporation's proxy statement details proposals for the 2024 annual meeting, including director elections, executive compensation, and shareholder proposals.

Vanguard Capital Management has filed a Schedule 13G reporting a 6.69% beneficial ownership stake in Danaher Corp.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Danaher Corp following an internal realignment.

The Vanguard Group filed an Amendment No. 8 to its Schedule 13G, disclosing an 8.63% beneficial ownership in Danaher Corp. common stock and detailing an internal realignment affecting its reporting structure.